Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Astria Therapeutics, Inc. Common Stock

Astria Therapeutics develops therapies for patients and families affected by allergic and immunologic diseases. Self-described as patient-focused, the company aims to bring life-changing treatments.

NASDAQ:ATXS